Document/ExhibitDescriptionPagesSize
1: 10-K 10-K - Pcrx - 12.31.2021 HTML 1.80M
2: EX-4.4 Instrument Defining the Rights of Security Holders HTML 497K
3: EX-4.5 Instrument Defining the Rights of Security Holders HTML 51K
4: EX-10.3 Material Contract HTML 44K
6: EX-10.36 Material Contract HTML 276K
7: EX-10.37 Material Contract HTML 161K
8: EX-10.38 Material Contract HTML 38K
5: EX-10.4 Material Contract HTML 45K
9: EX-21.1 Subsidiaries List HTML 33K
10: EX-23.1 Consent of Expert or Counsel HTML 31K
11: EX-31.1 Certification -- §302 - SOA'02 HTML 35K
12: EX-31.2 Certification -- §302 - SOA'02 HTML 35K
13: EX-32.1 Certification -- §906 - SOA'02 HTML 33K
19: R1 Cover HTML 96K
20: R2 Audit Information HTML 36K
21: R3 Consolidated Balance Sheets HTML 155K
22: R4 Consolidated Balance Sheets (Parenthetical) HTML 49K
23: R5 Consolidated Statements of Operations HTML 132K
24: R6 Consolidated Statements of Comprehensive Income HTML 58K
(Loss)
25: R7 Consolidated Statements of Stockholders' Equity HTML 118K
26: R8 Consolidated Statements of Stockholders' Equity HTML 33K
(Parenthetical)
27: R9 Consolidated Statements of Cash Flows HTML 166K
28: R10 Description of Business HTML 39K
29: R11 Summary of Significant Accounting Policies HTML 80K
30: R12 Recent Accounting Pronouncements HTML 49K
31: R13 Revenue HTML 88K
32: R14 Acquisitions HTML 79K
33: R15 Inventories HTML 40K
34: R16 Fixed Assets HTML 46K
35: R17 Leases HTML 60K
36: R18 Goodwill and Intangible Assets HTML 62K
37: R19 Accrued Expenses HTML 45K
38: R20 Debt HTML 110K
39: R21 Financial Instruments HTML 122K
40: R22 Stockholders' Equity HTML 56K
41: R23 Stock Plans HTML 138K
42: R24 Net Income (Loss) Per Share HTML 64K
43: R25 Income Taxes HTML 117K
44: R26 Employee Benefit Plans HTML 38K
45: R27 Acquisition-Related Charges and Product HTML 60K
Discontinuation, Net
46: R28 Commercial Partners and Other Agreements HTML 44K
47: R29 Related Party Transactions HTML 34K
48: R30 Commitments and Contingencies HTML 50K
49: R31 Subsequent Events HTML 33K
50: R32 Summary of Significant Accounting Policies HTML 151K
(Policies)
51: R33 Summary of Significant Accounting Policies HTML 60K
(Tables)
52: R34 Revenue (Tables) HTML 78K
53: R35 Acquisitions (Tables) HTML 69K
54: R36 Inventories (Tables) HTML 41K
55: R37 Fixed Assets (Tables) HTML 47K
56: R38 Leases (Tables) HTML 60K
57: R39 Goodwill and Intangible Assets (Tables) HTML 62K
58: R40 Accrued Expenses (Tables) HTML 43K
59: R41 Debt (Tables) HTML 79K
60: R42 Financial Instruments (Tables) HTML 113K
61: R43 Stockholders' Equity (Tables) HTML 51K
62: R44 Stock Plans (Tables) HTML 145K
63: R45 Net Income (Loss) Per Share (Tables) HTML 65K
64: R46 Income Taxes (Tables) HTML 113K
65: R47 Acquisition-Related Charges and Product HTML 50K
Discontinuation, Net (Tables)
66: R48 Description of Business (Details) HTML 35K
67: R49 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 47K
Concentration of Major Customers (Details)
68: R50 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -Fixed HTML 42K
Assets (Details)
69: R51 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 51K
Narrative (Details)
70: R52 Recent Accounting Pronouncements (Details) HTML 42K
71: R53 REVENUE - Sales and Valuation Accruals (Details) HTML 56K
72: R54 REVENUE - Narrative (Details) HTML 36K
73: R55 REVENUE- Disaggregation (Details) HTML 45K
74: R56 ACQUISITIONS - Narrative (Details) HTML 106K
75: R57 ACQUISITIONS - Contingent Consideration Flexion HTML 47K
Acquisition (Details)
76: R58 ACQUISITIONS - Schedule of Assets and Liabilities HTML 87K
Acquired (Details)
77: R59 ACQUISITIONS - Flexion Results (Details) HTML 37K
78: R60 ACQUISITIONS - Schedule of Pro Forma Information HTML 42K
(Details)
79: R61 INVENTORIES - Components of Inventory (Details) HTML 41K
80: R62 FIXED ASSETS - Schedule of Useful Lives (Details) HTML 51K
81: R63 FIXED ASSETS - Narrative (Details) HTML 45K
82: R64 LEASES - Narrative (Details) HTML 41K
83: R65 LEASES - Summary of operating lease cost and other HTML 48K
operating lease information (Details)
84: R66 LEASES - Schedule of maturities of operating lease HTML 50K
liabilities (Details)
85: R67 GOODWILL AND INTANGIBLE ASSETS - Goodwill HTML 43K
(Details)
86: R68 GOODWILL AND INTANGIBLE ASSETS - Narrative HTML 60K
(Details)
87: R69 GOODWILL AND INTANGIBLE ASSETS - Intangible Assets HTML 55K
(Details)
88: R70 Accrued Expenses (Details) HTML 54K
89: R71 DEBT - Carrying Value of Debt (Details) HTML 57K
90: R72 DEBT - Narrative (Details) HTML 264K
91: R73 DEBT - Schedule of Debt (Details) HTML 62K
92: R74 DEBT - Schedule of Interest Expense (Details) HTML 48K
93: R75 FINANCIAL INSTRUMENTS - Fair Value of Liabilities HTML 96K
Measured on a Recurring Basis (Details)
94: R76 FINANCIAL INSTRUMENTS - Narrative (Details) HTML 141K
95: R77 FINANCIAL INSTRUMENTS - Schedule of Fair Value HTML 49K
Inputs and Valuation (Details)
96: R78 FINANCIAL INSTRUMENTS - Contingent Consideration HTML 42K
Rollforward (Details)
97: R79 FINANCIAL INSTRUMENTS - Schedule of Investments at HTML 62K
Amortized Cost and Fair Value (Details)
98: R80 STOCKHOLDERS' EQUITY - Narrative (Details) HTML 44K
99: R81 Stockholders' Equity - Aoci (Details) HTML 51K
100: R82 STOCK PLANS - Narrative (Details) HTML 61K
101: R83 STOCK PLANS - Stock Incentive Plans (Details) HTML 52K
102: R84 STOCK PLANS - Compensation Expense (Details) HTML 50K
103: R85 STOCK PLANS - Stock Option Activity (Details) HTML 93K
104: R86 STOCK PLANS - Valuation Assumptions (Details) HTML 56K
105: R87 STOCK PLANS - RSU Activity (Details) HTML 61K
106: R88 Net Income (LOSS) PER SHARE - Calculation HTML 81K
(Details)
107: R89 Net Income (LOSS) PER SHARE - Antidilutive HTML 41K
Securities (Details)
108: R90 INCOME TAXES - Narrative (Details) HTML 110K
109: R91 INCOME TAXES - Current and Deferred Income Taxes HTML 66K
(Details)
110: R92 INCOME TAXES - Reconciliation of Effective Tax HTML 62K
Rate (Details)
111: R93 INCOME TAXES - Deferred Tax Assets and Liabilities HTML 64K
(Details)
112: R94 INCOME TAXES - Unrecognized Tax Benefits (Details) HTML 38K
113: R95 Employee Benefit Plans (Details) HTML 48K
114: R96 ACQUISITION-RELATED CHARGES AND PRODUCT HTML 59K
DISCONTINUATION, NET - Product Discontinuance
(Details)
115: R97 ACQUISITION-RELATED CHARGES AND PRODUCT HTML 46K
DISCONTINUATION, NET - Flexion (Details)
116: R98 ACQUISITION-RELATED CHARGES AND PRODUCT HTML 43K
DISCONTINUATION, NET - MyoScience (Details)
117: R99 Acquisition-Related Charges and Product HTML 35K
Discontinuation, Net - Nuance (Details)
118: R100 ACQUISITION-RELATED CHARGES AND PRODUCT HTML 36K
DISCONTINUATION, NET - DepoCyte Discontinuation
(Details)
119: R101 ACQUISITION-RELATED CHARGES AND PRODUCT HTML 33K
DISCONTINUATION, NET - Department of Justice
(Details)
120: R102 Commercial Partners and Other Agreements (Details) HTML 57K
121: R103 Related Party Transactions (Details) HTML 41K
122: R104 Commitments and Contingencies (Details) HTML 67K
123: R105 Subsequent Events (Details) HTML 44K
126: XML IDEA XML File -- Filing Summary XML 225K
124: XML XBRL Instance -- pcrx-20211231_htm XML 3.44M
125: EXCEL IDEA Workbook of Financial Reports XLSX 176K
15: EX-101.CAL XBRL Calculations -- pcrx-20211231_cal XML 315K
16: EX-101.DEF XBRL Definitions -- pcrx-20211231_def XML 1.42M
17: EX-101.LAB XBRL Labels -- pcrx-20211231_lab XML 2.82M
18: EX-101.PRE XBRL Presentations -- pcrx-20211231_pre XML 1.84M
14: EX-101.SCH XBRL Schema -- pcrx-20211231 XSD 293K
127: JSON XBRL Instance as JSON Data -- MetaLinks 640± 929K
128: ZIP XBRL Zipped Folder -- 0001396814-22-000021-xbrl Zip 1.07M
Granted Under Amended and Restated 2011 Stock Incentive Plan
1. Grant of Option.
This agreement evidences the grant by Pacira BioSciences, Inc., a Delaware corporation (the “Company”), on [GRANT DATE] (the “Grant
Date”) to [PARTICIPANT NAME], (the “Participant”), of an option to purchase, in whole or in part, on the terms provided herein and in the Company’s Amended and Restated 2011 Stock Incentive Plan (the “Plan”), a total of [NUMBER OF AWARDS GRANTED] shares (the “Shares”) of common stock, $0.001 par value per share, of the Company (“Common Stock”) at $[GRANT PRICE] per Share. Unless earlier terminated, this option shall expire at 5:00 p.m., Pacific time, on [EXPIRATION DATE] (the “Final
Exercise Date”).
It is intended that the option evidenced by this agreement shall not be an incentive stock option as defined in Section 422 of the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the “Code”). Except as otherwise indicated by the context, the term “Participant”, as used in this option, shall be deemed to include any person who acquires the right to exercise this option validly under its terms.
2. Vesting Schedule.
The option shares vest as follows: 25% of the option shares vest upon the one-year anniversary of the “Vesting Commencement Date”
and 6.25% of the option shares vest every three-months thereafter.
The right of exercise shall be cumulative so that to the extent the option is not exercised in any period to the maximum extent permissible it shall continue to be exercisable, in whole or in part, with respect to all Shares for which it is vested until the earlier of the Final Exercise Date or the termination of this option under Section 3 hereof or the Plan.
3. Exercise of Option.
(a) Form of Exercise. Each election to exercise this option shall be in writing, signed by the Participant, and received by the
Company at its principal office, accompanied by this agreement, and payment in full in the manner provided in the Plan. The Participant may purchase less than the number of Shares covered hereby, provided that no partial exercise of this option may be for any fractional share or for the lesser of (i) fifty (50) whole shares or (ii) the amount of unexercised option shares remaining under this option.
(b) Continuous Relationship with the Company Required. Except as otherwise provided in this Section 3, this option may not be exercised unless the Participant, at the time he or she exercises this option, is, and has been at all times since the Grant Date, an employee, officer or director of, or consultant or advisor to, the
Company or any other entity the employees, officers, directors, consultants, or advisors of which are eligible to receive option grants under the Plan (an “Eligible Participant”).
(c) Termination of Relationship with the Company. If the Participant ceases to be an Eligible Participant for any reason, then, except as provided in paragraphs (d) and (e) below, the right to exercise this option shall terminate three months after such cessation (but in no event after the Final Exercise Date), provided that
this option shall be exercisable only to the extent that the Participant was entitled to exercise this option on the date of such cessation. Notwithstanding the foregoing, if the Participant, prior to the Final Exercise Date, violates the non-competition or confidentiality provisions of any employment contract, confidentiality and nondisclosure agreement or other agreement between the Participant and the Company, the right to exercise this option shall terminate immediately upon such violation.
(d) Exercise Period Upon Death or Disability. If the Participant dies or becomes disabled (within the meaning of Section 22(e)(3) of the Code) prior to the Final Exercise
Date while he or she is an Eligible Participant and the Company has not terminated such relationship for “cause” as specified in paragraph (e) below, this option shall be exercisable, within the period of three years following the date of death or disability of the Participant, by the Participant (or in the case of death by an authorized transferee), provided that this option shall be exercisable only to the extent that this option was exercisable by the Participant on the date of his or her death or disability, and further provided that this option shall not be exercisable after the Final Exercise Date.
(e) Termination for Cause. If, prior to the Final Exercise
Date, the Participant’s employment or other relationship with the Company is terminated by the Company for Cause (as defined below), the right to exercise this option shall terminate immediately upon the effective date of such termination of employment or other relationship. If, prior to the Final Exercise Date, the Participant is given notice by the Company of the termination of his or her employment or other relationship by the Company for Cause, and the effective date of such employment or other termination is subsequent to the date of the delivery of such notice, the right to exercise this option shall be suspended from
the time of the delivery of such notice until the earlier of (i) such time as it is determined or otherwise agreed that the Participant’s employment or other relationship shall not be terminated for Cause as provided in such notice or (ii) the effective date of such termination of employment or other relationship (in which case the right to exercise this option shall, pursuant to the preceding sentence, terminate upon the effective date of such termination of employment or other relationship). If the Participant is party to an employment, consulting or severance agreement with the Company that contains a definition of “cause” for termination of employment or other relationship, “Cause” shall have the meaning ascribed to such term in such agreement. Otherwise, “Cause” shall mean willful misconduct by the Participant or willful
failure by the Participant to perform his or her responsibilities to the Company (including, without limitation, breach by the Participant of any provision of any employment, consulting, advisory, nondisclosure or other similar agreement between the Participant and the Company), as determined by the Company, which determination shall be conclusive. The Participant’s employment or other relationship shall be considered to have been terminated for “Cause” if the Company determines, within 30 days after the Participant’s resignation, that termination for Cause was warranted.
4.
Withholding.
No Shares will be issued pursuant to the exercise of this option unless and until the Participant pays to the Company, or makes provision satisfactory to the Company for payment of, any federal, state or local withholding taxes required by law to be withheld in respect of this option.
5. Transfer Restrictions.
This option may not be sold, assigned, transferred, pledged or otherwise encumbered by the Participant, either voluntarily or by operation of law, except by will or the
laws of descent and distribution, and, during the lifetime of the Participant, this option shall be exercisable only by the Participant; provided, however, that the Participant may transfer this option gratuitously to or for the benefit of any immediate family member of the Participant, family trust or other entity established for the benefit of the Participant and/or an immediate family member of the Participant if the Company would be eligible to use a Form S-8 under the Securities Act for the registration of the sale of the Shares to such proposed transferee; provided further, that the Company will not be required to recognize any such permitted transfer until such time as such permitted transferee, as a condition to such transfer, delivers to the
Company a written instrument in form and substance satisfactory to the Company confirming that such transferee will be bound by all the terms and conditions of this option.
6. Provisions of the Plan.
This option is subject to the provisions of the Plan (including the provisions relating to amendments to the Plan), a copy of which is furnished to the Participant with this option.
[SIGNATURE
PAGE FOLLOWS]
IN WITNESS WHEREOF, the Company has caused this option to be executed under its corporate seal by its duly authorized officer. This option shall take effect as a sealed instrument.
PACIRA BIOSCIENCES, INC.
By: ___________________________________
Name: ________________________________
Title: _________________________________
The
undersigned hereby accepts the foregoing option and agrees to the terms and conditions thereof. The undersigned hereby acknowledges receipt of a copy of the Company’s Amended and Restated 2011 Stock Incentive Plan.
PARTICIPANT:
By: ___________________________________
Name: _________________________________
SIGNATURE
PAGE TO NONSTATUTORY STOCK OPTION AGREEMENT
